Immunogenicity, Safety, Tolerability of a Plant-Made H5 VLP Influenza Vaccine

NCT01244867 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

255

Enrollment

INDUSTRY

Sponsor class

Conditions

Virus Diseases
RNA Virus Infections
Respiratory Tract Diseases
Respiratory Tract Infections

Interventions

BIOLOGICAL: 20 micrograms dose H5 VLP
BIOLOGICAL: 30 micrograms dose H5 VLP
BIOLOGICAL: 45 micrograms dose H5 VLP
BIOLOGICAL: 45 micrograms non-adjuvanted H5 VLP
BIOLOGICAL: Placebo

Sponsor

Medicago

Collaborators

[object Object]